Abstract:Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disease (GVHD)-prevention and treatment strategies. Most notably, the implementation of post-transplantation cyclophosphamide (PTCy) has dramatically increased the safety and availability of this life-saving therapy. Given reductions in nonrelapse mortality (NRM) with these advances, the HCT community has placed even greater emphasis on developing ways to reduce relapse - the leading cause of death after HCT. When using RIC HCT, protection from relapse relies predominantly on graft-versus-leukemia (GVL) reactions. Donor lymphocyte infusion (DLI), adoptive cellular therapy, checkpoint inhibition, and post-HCT maintenance strategies represent approaches under study that aim to augment or synergize with the GVL effects of HCT. Optimizing donor selection algorithms to leverage GVL represents another active area of research. Many of these strategies seek to harness the effects of T cells, which for decades were felt to be the primary mediators of GVL and the focus of investigation in relapse reduction. However, there is growing interest in capitalizing on the ability of natural killer (NK) cells to yield potent anti-tumor effects. A potential advantage of NK cell-based approaches over T cell-mediated is the potential to reduce NRM in addition to relapse. By decreasing infection, without increasing the risk of GVHD, NK cells may mitigate NRM, while still yielding relapse reduction through identification and clearance of cancer cells. Most T cell-focused relapse-prevention strategies must weigh the benefits of relapse reduction against the increased risk of NRM from GVHD. In contrast, NK cells have the potential to reduce both, potentially tipping the scales significantly in favor of survival. Here, we will review the role of NK cells in GVL, optimization of NK cell match or mismatch, and burgeoning areas of research in NK cell therapy such as adoptive transfer and chimeric antigen receptor (CAR) NK cells.

Natural Killer Group 2, Member D/NKG2D Ligands in Hematopoietic Cell Transplantation

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

Natural killer group 2D receptor and its ligands in cancer immune escape

Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation

Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications

Donor selection based on NK alloreactivity for patients with hematological malignancies

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses of CD94:NKG2A and Killer Immunoglobulin-Like Receptor Expression and Their Associations with Clinical Outcome

Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells

Natural killer cells in cancer immunotherapy

Natural Killer Cells: Tumor Surveillance and Signaling

A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review)

Targeting NKG2D/NKG2DL Axis In Multiple Myeloma Therapy

Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?

Natural killer cells in lung transplantation

Targeting natural killer cells and natural killer T cells in cancer

The Natural Cytotoxicity Receptors in Health and Disease

The Expression of Natural Killer Cells Inhibitory Receptors on Natural Killer Cells and T Lymphocytes and the Relationship with Acute Graft-Versus-host Disease